# The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type

> **NCT00216515** · PHASE4 · COMPLETED · sponsor: **Janssen Korea, Ltd., Korea** · enrollment: 102 (actual)

## Conditions studied

- Alzheimer Disease

## Interventions

- **DRUG:** galantamine hydrobromide

## Key facts

- **NCT ID:** NCT00216515
- **Lead sponsor:** Janssen Korea, Ltd., Korea
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2004-03
- **Primary completion:** —
- **Final completion:** 2005-11
- **Target enrollment:** 102 (ACTUAL)
- **Last updated:** 2011-01-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00216515

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00216515, "The Efficacy of Galantamine on the Attention and the Frontal Function of the Patients With Dementia of Alzheimer Type". Retrieved via MORVS 2026-10-30 from https://api.morvs.ai/clinical/NCT00216515. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*